Annual Report 2017

1. COMPLETED ACTIVITIES

1.1. Publications, guidelines and consensus documents:
- Med GL project published (Andrew Ullmann/Oliver Cornely): ESCMID Guidelines for the diagnosis and management of Aspergillus diseases (EFISG (including representatives from other ESCMID Study Groups), in collaboration with ECMM, ERS, ESGICH) (SG publication, CMI 2018).
- Azole-resistance in *Aspergillus terreus* and related species: an emerging problem or a rare phenomenon?, EFISG, ECMM and ISHAM cooperation; to be published in Frontiers in Medical Microbiology in 2018

1.2. Presentations on behalf of the Study Group at scientific meetings:
- ECCMID 2017 Vienna, EFISG, ESCMID Networking Corner Poster ENC001
- Oral presentation on “News from ESCMID-EFISG”, 2nd Inform Meeting, 5-6 May 2017, Dubai
- Oral presentation on “Epidemiology of antifungal resistances in Europe”, 27-28 May 2017, Taiwan (Cornelia Lass-Flörl)
- Oral presentation on “How to diagnose fungal infections/Summary of ESCMID guidelines”, OPATHY Summer School 27 August – 1 September 2017, Jena/Germany (Cornelia Lass-Flörl)
- “Diagnosing filamentous fungal infections in immunocompromised patients applying computed tomography-guided percutaneous lung biopsies: a 12 years’ experience”, DMykG 31 August – 2 September 2017, Münster/Germany (Cornelia Lass-Flörl)
- ECM/EFISG symposium “Multidrug resistance in fungi? A formidable foe”, TIMM 6-9 October 2017, Belgrade/Serbia
- EORTC/EFISG symposium “Invasive aspergillosis management in 2017 and beyond”, TIMM 6-9 October 2017, Belgrade/Serbia
1.3. Proposals for scientific & educational sessions at ECCMID:
@ECCMID 2017 Vienna:

Selected:
- ECCMID 2017 Vienna 1-hour Symposium: Top papers in mycology; Organizer(s): EFISG (accepted)
- ECCMID 2017 Vienna 2-hour Educational Workshop: The mucormycosis workshop; Organizer(s): EFISG, ESGICH, MSGERC (accepted)
- ECCMID 2017 Vienna Meet-the-Expert Session: Difficult-to-treat fungal infections (eye and CNS); Organizer(s): EFISG, ESGIB (accepted)

Not selected:
- ECCMID 2017 Vienna 1-hour Symposium: Immune responses against fungi - differences and similarities; Organizer(s): EFISG (not selected)
- ECCMID 2017 Vienna 1-hour Symposium: Immune responses against fungi - differences and similarities; Organizer(s): EFISG (not selected)
- ECCMID 2017 Vienna 2-hour Educational Workshop: Antifungal susceptibility testing; Organizer(s): EFISG (not selected)
- ECCMID 2017 Vienna 2-hour Symposium: Biofilm formation in fungi - a challenge for the clinician; Organizer(s): EFISG (not selected)
- ECCMID 2017 Vienna 2-hour Symposium: Controversies in fungal guideline development - clinical utility vs. supportive evidence; Organizer(s): EFISG, ICMS (not selected)
- ECCMID 2017 Vienna 2-hour Symposium: Experimental antifungal drugs - new agents, different delivery systems, different indications; Organizer(s): EFISG (not selected)
- ECCMID 2017 Vienna 2-hour Symposium: Fungal emergencies - diagnosing and treating without delay; Organizer(s): EFISG, ECMM (not selected)
- ECCMID 2017 Vienna 2-hour Symposium: Respiratory infections in the immunocompromised patient; Organizer(s): ESGLI, ESGMD, EFISG (not selected)
- ECCMID 2017 Vienna 4-hour Educational Workshop: Microbes as causes of non-infectious diseases; Organizer(s): TAE, ESGCP, EFISG, ESGIE (not selected)

1.4. Organization of scientific meetings and workshops outside ECCMID:
- EORTC/ESCMID brainstorming meeting, 14 February 2017, Brussels, Belgium (with official representatives by EFISG, EPASG, ESGAP, ESGARS, ESGBIS, ESGCIP, ESGICH, ESGMD)
- IV Meeting of the ECMM/ISHAM Working Group Fungal Respiratory Infections in Cystic Fibrosis (Fri-CF), Osuna (Spain) 5-6 June 2017

1.5. Organization of educational activities outside ECCMID:
Global Chinese Association for Clinical Microbiology and Infectious Diseases (GCACMID)

- ESCMID course: Improving the Diagnosis of Bloodstream Infections – Advancing Technology and Quality for Better Care. Nice, France, 28 – 31 March 2017; organizers: ESCMID Study Group for Bloodstream Infections and Sepsis (ESGBIS), ESCMID Fungal Infection Study Group (EFISG), ESCMID Study Group for Biofilms (ESGB), ESCMID Study Group for Epidemiological Markers (ESGEM), ESCMID Study Group for Molecular Diagnostics (ESGMD), ESCMID Study Group for Staphylococci and Staphylococcal Diseases (ESGS), University of Nice-Sofia Antipolis/Université Côte d’Azur

1.6. Funded research projects (especially collaborative projects):

- Medical Guideline project EFISG (Andrew Ullmann/Oliver Cornely) [ESGICH]: Aspergillus (Close to publication)
- SG Research Funding 11901 (Ana Alastruey-Izquierdo, EFISG): MixInYest: a multicenter survey on mixed yeast infections in Europe (planned to run until Sep 2019)
- European survey on antifungal therapy duration for invasive aspergillosis (Fanny Lanternier, Olivier Lortholary, together with EFISG)
- Scedo-Lung: Practice survey on Scedosporium colonization and infection in lung transplant recipients (ESCMID-EFISG and ESGICH Survey) (Blandine Rammaert & Olivier Lortholary)

1.7. Other important activities:

- None

2. PLANNED ACTIVITIES

- EFISG representative at AAA 8th Advances Against Aspergillosis 2018
- Project with EORTC “Revision of antifungal strategies definitions for invasive fungal infections (proven/probable/possible) in patients with haematological malignancies in the real life
- Medical guidelines for paediatric invasive aspergillosis
- Revision of the medical guidelines for rare fungi, Candida and Mucorales
- EFISG/ECMM joint symposium “Aspergillus guidelines” at ISHAM 2018
- Aspergillus guideline publication
- Submitted: SG Research Funding 11908 (Yubhisha Dabas, EFISG): Epidemiology and dynamics of azole resistant Aspergillus among patients with cystic fibrosis (CF) (planned to run until Jan 2019)
- Submitted: SG Research Funding 13736 (Bart Rijnders, EFISG): Detection of azole resistance inducing mutations on DNA extracted directly from serum or plasma of
immunocompromised patients with an invasive aspergillus infection (planned to run until Oct 2019)

- Publication: Azole resistance in A. terreus (EFISG-ECMM), 2018
- Position paper on Medical Mycology (ECMM, GAFFI, EFISG, ISHAM)

@ ECCMID 2018 Madrid:

**Selected:**

- ECCMID 2018 Madrid Educational Workshop (2 hours) (Accepted): It’s Saturday morning and we have a yeast in the blood culture in a patient with cancer; co-arranged with: European Organisation for Research and Treatment of Cancer, ESGCIP - ESCMID SG for Infections in Critically Ill Patients, EFISG - ESCMID Fungal Infection SG
- ECCMID 2018 Madrid Symposium (1 hour) (Accepted): Influenza-associated aspergillosis; co-arranged with: EFISG - ESCMID Fungal Infection SG
- ECCMID 2018 Madrid Symposium (1 hour) (Accepted): Top papers in mycology; co-arranged with: EFISG - ESCMID Fungal Infection SG

**Not selected:**

- ECCMID 2018 Madrid Meet-the-Expert (Not Selected): Current approaches to diagnosis and control of IFDs in pediatric patients; co-arranged with: EFISG - ESCMID Fungal Infection SG
- ECCMID 2018 Madrid Symposium (2 hour) (Not Selected): Perspectives for the improved management of invasive mold infections; co-arranged with: EFISG - ESCMID Fungal Infection SG, ESGICH - ESCMID SG for Infections in Compromised Hosts
- ECCMID 2018 Madrid Symposium (2 hour) (Not Selected): Syndromic approach in immunosuppressed hosts; co-arranged with: EFISG - ESCMID Fungal Infection SG, International Immunocompromised Host Society

Outside ECCMID

- ESCMID course: Antifungal resistance in Candida and Aspergillus: from clinic to clinical laboratory. Delhi, India, 19 - 21 September 2018; organizers: ESCMID Fungal Infection Study Group – EFISG
- Conference on antimicrobial resistance from bench to practice. Havanna, Cuba, 26 – 28 September 2018 (participation as representative of EFISG)
- The 5th International One Health Congress. 22 – 25 June 2018, Saskatoon/Canada (participation as representative of EFISG)
3. **ADMINISTRATION**

3.1. **Number of current members:**

149 SG members (as of end of December 2017)

3.2. **Agenda for General Assembly/Business Meeting:**

Agenda will be circulated before ECCMID 2018

4. **FINANCES**

4.1. **Revenues and expenses**

Approved by Treasurer.

4.2. **Balance**

EUR 6,256.29 (as of end of December 2017)